BI
Publicaties op Oncologisch.com
Circulating kidney injury molecule-1 (KIM-1) and association with outcome to adjuvant immunotherapy in renal cell car...
Avelumab + axitinib versus sunitinib as eerstelijns treatment for patiënten met gevorderd renal cell carcinoma: final...
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year...
JAVELIN Renal 101: geactualiseerde werkzaamheid van avelumab-axitinib versus sunitinib bij mRCC